May 12, 2025 01:56 AM GMT Eli Lilly & Co. | North America Tidbits from Zepbound vs. Wegovy SURMOUNT-5 obesity publication Investigators published SURMOUNT-5 Ph3 obesity data from a head-to-head trial of LLY's Zepbound (Tirzepatide MTD 10/15mg) vs. Novo's Wegovy (Semaglutide MTD 1.7/2.4mg) in the New England Journal of Medicine (LINK). Recall top-line data from the trial were reported in Dec 2024, see our prior note HERE. In the Zepbound group, 89.3% of the participants received at least one 15mg dose, and i ...